An investigation on behalf of investors in Menlo Therapeutics Inc. (NASDAQ: MNLO) shares over potential wrongdoing at Menlo Therapeutics Inc. was announced.
San Diego, CA -- (SBWIRE) -- 07/11/2018 -- An investigation was announced for investors in NASDAQ: MNLO shares concerning potential breaches of fiduciary duties by certain directors at Menlo Therapeutics Inc. .
Investors who purchased shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Menlo Therapeutics Inc. (NASDAQ: MNLO officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
On May 9, 2018, Menlo Therapeutics Inc reported its first quarter 2018 financial results. Menlo Therapeutics Inc reported a net loss of $12.7 million for the first quarter of 2018, compared to a net loss of $5.5 million for the same period in 2017. Furthermore, Menlo Therapeutics Inc, adjusted its financial outlook for the full year 2018. Menlo Therapeutics Inc said that it is lowering its operating expense guidance for the full year 2018 to a range of approximately $68.0 to $78.0 million.
Those who purchased shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels